{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:50:56Z","timestamp":1783032656310,"version":"3.54.6"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Die Ursache der prim\u00e4r sklerosierenden Cholangitis (PSC) bleibt unklar und erkl\u00e4rt das Fehlen einer kausalen Therapie. Die differenzialdiagnostische Abgrenzung zur noch selteneren IgG4-assoziierten Cholangitis (IAC) gelingt uns immer besser. Fortschritte im Wissen um unterschiedliche klinische Verl\u00e4ufe, Verbesserungen in der nichtinvasiven Diagnostik durch moderne Magnetresonanzbildgebung und die Einf\u00fchrung der Leberelastographie f\u00fchrten zur Entwicklung verbesserter Prognosemodelle. Die Evidenz f\u00fcr Empfehlungen zur medikament\u00f6sen (z.\u202fB. Ursodesoxychols\u00e4ure) oder endoskopischen Therapie (z.\u202fB. Ballondilatation und\/oder Stenteinlage) bei PSC bleibt gering. Hingegen werden die Langzeitergebnisse der Lebertransplantation bei PSC stetig besser. Mangels hochsensitiver und spezifischer Screeningmethoden gelingt die Fr\u00fcherkennung des cholangiozellul\u00e4ren Karzinoms (CCC) als wichtigste Komplikation selten. Die stetige Verbesserung von ERCP und direkter Cholangioskopie in Kombination mit molekularbiologischen und FISH-Analysen der gewonnenen Gewebsproben ist f\u00fcr die verfeinerte Diagnostik vielversprechend. Aufgrund des deutlich erh\u00f6hten Risikos f\u00fcr kolorektale Karzinome wird bei Vorliegen einer chronisch-entz\u00fcndlichen Darmerkrankung (CED) die j\u00e4hrliche Koloskopie empfohlen. Errungenschaften in der Fr\u00fchdiagnostik und die erfolgreiche Testung neuer Therapiemodalit\u00e4ten lassen auf eine stetige Verbesserung in der Betreuung dieser komplexen PatientInnen hoffen.<\/jats:p>","DOI":"10.1007\/s00108-024-01697-0","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T08:03:05Z","timestamp":1710748985000},"page":"347-356","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prim\u00e4r sklerosierende Cholangitis\u00a0\u2013 Diagnose und Therapie 2024","Primary sclerosing cholangitis\u2014Diagnosis and treatment 2024"],"prefix":"10.1007","volume":"65","author":[{"given":"Michael","family":"Trauner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emina","family":"Halilbasic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Tatscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Fickert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"issue":"10139","key":"1697_CR1","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1016\/S0140-6736(18)30300-3","volume":"391","author":"JK Dyson","year":"2018","unstructured":"Dyson\u00a0JK et\u00a0al (2018) Primary sclerosing cholangitis. Lancet 391(10139):2547\u20132559","journal-title":"Lancet"},{"issue":"25","key":"1697_CR2","first-page":"2501","volume":"375","author":"KN Lazaridis","year":"2016","unstructured":"Lazaridis\u00a0KN, LaRusso\u00a0NF (2016) Primary Sclerosing Cholangitis. N\u00a0Engl J Med 375(25):2501\u20132502","journal-title":"N Engl J Med"},{"issue":"6","key":"1697_CR3","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","volume":"67","author":"TH Karlsen","year":"2017","unstructured":"Karlsen\u00a0TH et\u00a0al (2017) Primary sclerosing cholangitis\u2014a\u00a0comprehensive review. J\u00a0Hepatol 67(6):1298\u20131323","journal-title":"J Hepatol"},{"issue":"3","key":"1697_CR4","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","volume":"77","author":"European Association for the Study of the Liver. Electronic address, e.e.e.","year":"2022","unstructured":"European Association for the Study of the Liver. Electronic address, e.e.e., L. European Association for the Study (2022) EASL Clinical Practice Guidelines on sclerosing cholangitis. J\u00a0Hepatol 77(3):761\u2013806","journal-title":"J Hepatol"},{"issue":"2","key":"1697_CR5","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s00330-021-08147-7","volume":"32","author":"SK Venkatesh","year":"2022","unstructured":"Venkatesh\u00a0SK et\u00a0al (2022) Reporting standards for primary sclerosing cholangitis using MRI and MR cholangiopancreatography: guidelines from MR Working Group of the International Primary Sclerosing Cholangitis Study Group. Eur Radiol 32(2):923\u2013937","journal-title":"Eur Radiol"},{"issue":"6","key":"1697_CR6","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1177\/2050640620934911","volume":"8","author":"JM Lohr","year":"2020","unstructured":"Lohr\u00a0JM et\u00a0al (2020) European Guideline on IgG\u00a04-related digestive disease\u2014UEG and SGF evidence-based recommendations. United European Gastroenterol\u00a0J 8(6):637\u2013666","journal-title":"United European Gastroenterol J"},{"issue":"6","key":"1697_CR7","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jhep.2017.02.013","volume":"66","author":"European Society of Gastrointestinal, E., e.e.e.","year":"2017","unstructured":"European Society of Gastrointestinal, E., e.e.e., European Association for the Study of the Liver., Electronic address, and L.\u00a0European Association for the Study (2017) Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. J\u00a0Hepatol 66(6):1265\u20131281","journal-title":"J Hepatol"},{"issue":"6","key":"1697_CR8","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1002\/hep.26565","volume":"58","author":"K Boonstra","year":"2013","unstructured":"Boonstra\u00a0K et\u00a0al (2013) Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 58(6):2045\u20132055","journal-title":"Hepatology"},{"issue":"1","key":"1697_CR9","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/hep.27825","volume":"62","author":"M Vesterhus","year":"2015","unstructured":"Vesterhus\u00a0M et\u00a0al (2015) Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. Hepatology 62(1):188\u2013197","journal-title":"Hepatology"},{"issue":"4","key":"1697_CR10","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1053\/j.gastro.2013.12.030","volume":"146","author":"C Corpechot","year":"2014","unstructured":"Corpechot\u00a0C et\u00a0al (2014) Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis. Gastroenterology 146(4):970\u2013979 (quiz e15-6)","journal-title":"Gastroenterology"},{"issue":"2","key":"1697_CR11","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1053\/j.gastro.2014.04.058","volume":"147","author":"H Ehlken","year":"2014","unstructured":"Ehlken\u00a0H, Lohse\u00a0AW, Schramm\u00a0C (2014) Transient elastography in primary sclerosing cholangitis\u2014the value as a\u00a0prognostic factor and limitations. Gastroenterology 147(2):542\u2013543","journal-title":"Gastroenterology"},{"issue":"1","key":"1697_CR12","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/hep.26620","volume":"59","author":"A Ruiz","year":"2014","unstructured":"Ruiz\u00a0A et\u00a0al (2014) Radiologic course of primary sclerosing cholangitis: assessment by three-dimensional magnetic resonance cholangiography and predictive features of progression. Hepatology 59(1):242\u2013250","journal-title":"Hepatology"},{"key":"1697_CR13","doi-asserted-by":"publisher","first-page":"109884","DOI":"10.1016\/j.ejrad.2021.109884","volume":"142","author":"A Grigoriadis","year":"2021","unstructured":"Grigoriadis\u00a0A et\u00a0al (2021) Assessment of prognostic value and interreader agreement of ANALI scores in patients with primary sclerosing cholangitis. Eur J Radiol 142:109884","journal-title":"Eur J Radiol"},{"issue":"12","key":"1697_CR14","doi-asserted-by":"publisher","first-page":"100595","DOI":"10.1016\/j.jhepr.2022.100595","volume":"4","author":"A Grigoriadis","year":"2022","unstructured":"Grigoriadis\u00a0A et\u00a0al (2022) Development of a\u00a0prognostic MRCP-score (DiStrict) for individuals with large-duct primary sclerosing cholangitis. JHEP Rep 4(12):100595","journal-title":"JHEP Rep"},{"issue":"11","key":"1697_CR15","doi-asserted-by":"publisher","first-page":"100577","DOI":"10.1016\/j.jhepr.2022.100577","volume":"4","author":"N Cazzagon","year":"2022","unstructured":"Cazzagon\u00a0N et\u00a0al (2022) Quantitative magnetic resonance cholangiopancreatography metrics are associated with disease severity and outcomes in people with primary sclerosing cholangitis. JHEP Rep 4(11):100577","journal-title":"JHEP Rep"},{"issue":"3","key":"1697_CR16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.dld.2022.10.015","volume":"55","author":"L Cristoferi","year":"2023","unstructured":"Cristoferi\u00a0L et\u00a0al (2023) A\u00a0quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis. Dig Liver Dis 55(3):373\u2013380","journal-title":"Dig Liver Dis"},{"issue":"1","key":"1697_CR17","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/hep.30085","volume":"71","author":"JE Eaton","year":"2020","unstructured":"Eaton\u00a0JE et\u00a0al (2020) Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease: A\u00a0Derivation and Validation Study Using Machine Learning. Hepatology 71(1):214\u2013224","journal-title":"Hepatology"},{"issue":"5","key":"1697_CR18","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.jhep.2019.06.012","volume":"71","author":"JC Goet","year":"2019","unstructured":"Goet\u00a0JC et\u00a0al (2019) Validation, clinical utility and limitations of the Amsterdam-Oxford model for primary sclerosing cholangitis. J\u00a0Hepatol 71(5):992\u2013999","journal-title":"J Hepatol"},{"issue":"11","key":"1697_CR19","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1055\/s-0043-120199","volume":"55","author":"Deutsche Gesellschaft fur Gastroenterologie, V.-u.S.","year":"2017","unstructured":"Deutsche Gesellschaft fur Gastroenterologie, V.-u.S. et\u00a0al (2017) Practice guideline autoimmune liver diseases\u2014AWMF-Reg. No. 021-27. Z\u00a0Gastroenterol 55(11):1135\u20131226","journal-title":"Z Gastroenterol"},{"issue":"4","key":"1697_CR20","doi-asserted-by":"publisher","first-page":"100649","DOI":"10.1016\/j.jhepr.2022.100649","volume":"5","author":"N Cazzagon","year":"2023","unstructured":"Cazzagon\u00a0N et\u00a0al (2023) Protective potential of the gallbladder in primary sclerosing cholangitis. JHEP Rep 5(4):100649","journal-title":"JHEP Rep"},{"issue":"3","key":"1697_CR21","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jhep.2022.11.011","volume":"78","author":"C Villard","year":"2023","unstructured":"Villard\u00a0C et\u00a0al (2023) Prospective surveillance for cholangiocarcinoma in unselected individuals with primary sclerosing cholangitis. J\u00a0Hepatol 78(3):604\u2013613","journal-title":"J Hepatol"},{"issue":"11","key":"1697_CR22","doi-asserted-by":"publisher","first-page":"100553","DOI":"10.1016\/j.jhepr.2022.100553","volume":"4","author":"J Eliasson","year":"2022","unstructured":"Eliasson\u00a0J et\u00a0al (2022) Survey uncovering variations in the management of primary sclerosing cholangitis across Europe. JHEP Rep 4(11):100553","journal-title":"JHEP Rep"},{"issue":"1 Suppl","key":"1697_CR23","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","volume":"62","author":"U Beuers","year":"2015","unstructured":"Beuers\u00a0U et\u00a0al (2015) New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J\u00a0Hepatol 62(1 Suppl):S25\u2013S37","journal-title":"J Hepatol"},{"issue":"2","key":"1697_CR24","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/hep.32771","volume":"77","author":"CL Bowlus","year":"2023","unstructured":"Bowlus\u00a0CL et\u00a0al (2023) AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology 77(2):659\u2013702","journal-title":"Hepatology"},{"issue":"3","key":"1697_CR25","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/hep.27180","volume":"60","author":"JH Tabibian","year":"2014","unstructured":"Tabibian\u00a0JH, Lindor\u00a0KD (2014) Ursodeoxycholic acid in primary sclerosing cholangitis: if withdrawal is bad, then administration is good (right?). Hepatology 60(3):785\u2013788","journal-title":"Hepatology"},{"issue":"11","key":"1697_CR26","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1007\/s00535-022-01914-3","volume":"57","author":"T Arizumi","year":"2022","unstructured":"Arizumi\u00a0T et\u00a0al (2022) Ursodeoxycholic acid is associated with improved long-term outcome in patients with primary sclerosing cholangitis. J\u00a0Gastroenterol 57(11):902\u2013912","journal-title":"J Gastroenterol"},{"issue":"10","key":"1697_CR27","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1093\/ibd\/izaa317","volume":"27","author":"C Kulkarni","year":"2021","unstructured":"Kulkarni\u00a0C et\u00a0al (2021) Association of Anti-TNF Therapy With Increased Risk of Acute Cholangitis in Patients With Primary Sclerosing Cholangitis. Inflamm Bowel Dis 27(10):1602\u20131609","journal-title":"Inflamm Bowel Dis"},{"issue":"13","key":"1697_CR28","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.1016\/j.cgh.2023.01.014","volume":"21","author":"I Schregel","year":"2023","unstructured":"Schregel\u00a0I et\u00a0al (2023) Evaluation of Tofacitinib in Primary Sclerosing Cholangitis and Associated Colitis: A\u00a0Multicenter, Retrospective Study. Clin Gastroenterol Hepatol 21(13):3448\u20133450","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"1697_CR29","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/hep.31560","volume":"73","author":"MR Deneau","year":"2021","unstructured":"Deneau\u00a0MR et\u00a0al (2021) Oral Vancomycin, Ursodeoxycholic Acid, or No Therapy for Pediatric Primary Sclerosing Cholangitis: A\u00a0Matched Analysis. Hepatology 73(3):1061\u20131073","journal-title":"Hepatology"},{"issue":"3","key":"1697_CR30","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1053\/j.gastro.2018.05.034","volume":"155","author":"CY Ponsioen","year":"2018","unstructured":"Ponsioen\u00a0CY et\u00a0al (2018) No Superiority of Stents vs Balloon Dilatation for Dominant Strictures in Patients With Primary Sclerosing Cholangitis. Gastroenterology 155(3):752\u2013759 e5","journal-title":"Gastroenterology"},{"issue":"4","key":"1697_CR31","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/j.1572-0241.2001.03690.x","volume":"96","author":"M Kaya","year":"2001","unstructured":"Kaya\u00a0M et\u00a0al (2001) Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol 96(4):1059\u20131066","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"1697_CR32","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1007\/s00464-021-08522-x","volume":"36","author":"W Sbeit","year":"2022","unstructured":"Sbeit\u00a0W et\u00a0al (2022) Three-months duration of fully-covered metal stent for refractory dominant extra-hepatic biliary stricture among primary sclerosing cholangitis patients: efficacy and safety. Surg Endosc 36(4):2412\u20132417","journal-title":"Surg Endosc"},{"issue":"2","key":"1697_CR33","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.gie.2014.06.030","volume":"81","author":"U Navaneethan","year":"2015","unstructured":"Navaneethan\u00a0U et\u00a0al (2015) ERCP-related adverse events in patients with primary sclerosing cholangitis. Gastrointest Endosc 81(2):410\u2013419","journal-title":"Gastrointest Endosc"},{"issue":"4","key":"1697_CR34","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/ajg.2008.161","volume":"104","author":"SY Bangarulingam","year":"2009","unstructured":"Bangarulingam\u00a0SY et\u00a0al (2009) Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis. Am J Gastroenterol 104(4):855\u2013860","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"1697_CR35","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1177\/2050640620912608","volume":"8","author":"V Koskensalo","year":"2020","unstructured":"Koskensalo\u00a0V et\u00a0al (2020) Diclofenac does not reduce the risk of acute pancreatitis in patients with primary sclerosing cholangitis after endoscopic retrograde cholangiography. United European Gastroenterol\u00a0J 8(4):462\u2013471","journal-title":"United European Gastroenterol J"},{"issue":"5","key":"1697_CR36","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.gie.2013.09.015","volume":"79","author":"G Trikudanathan","year":"2014","unstructured":"Trikudanathan\u00a0G et\u00a0al (2014) Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a\u00a0systematic review and meta-analysis. Gastrointest Endosc 79(5):783\u2013789","journal-title":"Gastrointest Endosc"},{"issue":"12","key":"1697_CR37","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/j.cgh.2019.07.011","volume":"17","author":"CL Bowlus","year":"2019","unstructured":"Bowlus\u00a0CL, Lim\u00a0JK, Lindor\u00a0KD (2019) AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With Primary Sclerosing Cholangitis: Expert Review. Clin Gastroenterol Hepatol 17(12):2416\u20132422","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11\u201312","key":"1697_CR38","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/apt.13817","volume":"44","author":"B Njei","year":"2016","unstructured":"Njei\u00a0B et\u00a0al (2016) Systematic review with meta-analysis: endoscopic retrograde cholangiopancreatography-based modalities for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Aliment Pharmacol Ther 44(11\u201312):1139\u20131151","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01697-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-024-01697-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01697-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T11:20:34Z","timestamp":1711106434000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-024-01697-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1697"],"URL":"https:\/\/doi.org\/10.1007\/s00108-024-01697-0","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]},"assertion":[{"value":"5 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Trauner: Beratungst\u00e4tigkeit f\u00fcr AbbVie, Albireo, BiomX, Boehringer Ingelheim, CymaBay, Falk, Gilead, Genfit, HighTide, Ibsen, Intercept, Janssen, MSD, Novartis, Pliant, Phenex, Regulus, Rectify, Siemens, Shire; Vortragst\u00e4tigkeit f\u00fcr BMS, Falk, Gilead, Intercept, MSD, Madrigal, Roche; Reisekostenunterst\u00fctzung durch AbbVie, Falk, Gilead, Intercept, Janssen, Roche; Forschungsf\u00f6rderungen von Albireo, Alnylam, CymaBay, Falk, Gilead, Intercept, MSD, Takeda, Ultragenyx; Patente: Miterfinder von Patenten f\u00fcr den medizinischen Gebrauch von norUDCA\/Noruchols\u00e4ure (Diensterfindung). E.\u00a0Halilbasic: Beratungst\u00e4tigkeit f\u00fcr Falk, Novartis, Intercept; Vortragst\u00e4tigkeit f\u00fcr Falk, Intercept; Reisekostenunterst\u00fctzung durch Falk, Ibsen, AbbVie. E.\u00a0Tatscher: Beratungst\u00e4tigkeit f\u00fcr Falk und Takeda. P.\u00a0Fickert: Beratungst\u00e4tigkeit f\u00fcr Falk; Patente: Miterfinder von Patenten f\u00fcr den medizinischen Gebrauch von norUDCA\/Noruchols\u00e4ure (Diensterfindung).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}